Anika Therapeutics (ANIK) Misses Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro boost AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.50 +0.29%
Revenue Growth %: +5.9%
Financial Fact:
Provision for income taxes: 4.83M
Today's EPS Names:
OMID, BCML, CZNC, More
Revenue Growth %: +5.9%
Financial Fact:
Provision for income taxes: 4.83M
Today's EPS Names:
OMID, BCML, CZNC, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of ($0.13), $0.05 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $28.22 million versus the consensus estimate of $28.15 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- US Treasury: 'Authorizing Wind Down Activities...the Offloading of Cargo Involving Certain Persons or Vessels Blocked on October 21, 2026'
- StoneX Starts Gowell Energy Technology (GOW) at Buy
- Pinnacle Financial Partners Halted For News Pending
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
